Misoprostol (Cytotec)

ISSN 0256-5004 (Print)

AIMS Journal Vol 13 No 3

IMPORTANT DRUG WARNING CONCERNING UNAPPROVED USE OF INTRAVAGINAL OR ORAL MISOPROSTOL IN PREGNANT WOMEN FOR INDUCTION OR LABOR OR ABORTION

August 23, 2000
Re: Cytotec (misoprostol)

Dear Health Care Practitioner:

The purpose of this letter is to remind you that Cytotec administration by any route is contraindicated in women who are pregnant because it can cause abortion. Cytotec is not approved for the induction of labor or abortion.

Cytotec is indicated for the prevention of NSAID (nonsteroidal anti- inflammatory drugs, including aspirin) - induced gastric ulcers in patients at high risk of complications from gastric ulcer, eg the elderly and patients with concomitant debilitating disease, as well as patients at high risk of developing gastric ulceration, such as patients with a history of ulcer.

The uterotonic effect of cytotec is an inherent property of prostaglandin E1 (PGE1), of which Cytotec is a stable, orally active, synthetic analog. Searle has become aware of some instances where Cytotec, outside of its approved indication, was used as a cervical ripening agent prior to termination of pregnancy, or for induction of labor, in spite of the specific contraindications to its use during pregnancy.

Serious adverse events reported following off-label use of Cytotec in pregnant women include maternal or fetal death; uterine hyperstimulation, rupture or perforation requiring uterine surgical repair, hysterectomy or salpingo-oophorectomy, amniotic fluid embolism, severe vaginal bleeding, retained placenta, shock, fetal bradycardia and pelvic pain.

Searle has not conducted research concerning the use of Cytotec for cervical ripening prior to termination of pregnancy or for induction of labor, nor does Searle intend to study or support these uses. Therefore, Searle is unable to provide risk information for Cytotec when it is used for such purposes. In addition to the known and unknown acute risks to the mother and fetus, the effect of Cytotecon the later growth, development and functional maturation of the child when Cytotec is used for induction of labor or cervical ripening has not been established.

Searle promotes the use of Cytotec only for its approved indication. Please read the enclosed updated complete Prescribing Information for Cytotec.

Further information may be obtained by calling 1-800-323-4204.

Michael Cullen MD
Medical Director, US
Searle

Latest Content

Journal

« »

AIMS during the 1970s

AIMS Journal, 2020, Vol 32, No 3 By Shane Ridley AIMS Trustee I decided to read through the 1970s , starting with the Quarterly Newsletter for September 1970 which was ty…

Read more

AIMS during the 1960s

AIMS Journal, 2020, Vol 32, No 3 by Dorothy Brassington AIMS Trustee and Treasurer It has been fascinating to read the early newsletters and discover exactly what AIMS wa…

Read more

AIMS during the 1980s

AIMS Journal, 2020, Vol 32, No 3 by Verina Henchy AIMS Trustee I was delighted to hear that the theme for this Journal is to look back over a 60 year history of maternity…

Read more

Events

« »

AIMS 60th Anniversary Event - Confe…

POSTPONED FROM JUNE 2020 Making a difference past and future The purpose of the day is to celebrate what Birth Activists in general and AIMS in particular have achieved,…

Read more

ARM National Conference 2020: "How…

Chair: Professor Soo Downe, University of Central Lancashire Dr Gloria Esegbona, OBGYN and Winston Churchill Fellow 2015 Kings College Learning Institute Dr Gloria Esegbo…

Read more

NICE Annual Conference 2020

Registration for the NICE Annual Conference 2020 will open on 22 January 2020. For more details and to register your interest, please visit http://www.niceconference.org.…

Read more

Latest Campaigns

« »

AIMS submission to the Health and S…

AIMS' evidence to the Health and Social Care Select Committee - Safety of Maternitys Services in England In July 2020, the UK Parliament's Health and Social Care Select C…

Read more

AIMS comments on RCOG - Restoration…

A prioritisation framework for care in response to COVID-19 Version 2.1: Published Friday 26 June 2020 AIMS has welcomed the RCOG document Restoration and Recovery: prior…

Read more

AIMS' evidence to the Health and So…

AIMS' evidence to the Health and Social Care Select Committee On April 22, the UK Parliament's Health and Social Care Select Committee opened an inquiry ​into the plannin…

Read more